ADMA Biologics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 14/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 27.25.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ADMA Biologics Inc's Score
Industry at a Glance
Industry Ranking
14 / 158
Overall Ranking
41 / 4562
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
27.250
Target Price
+40.54%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ADMA Biologics Inc Highlights
StrengthsRisks
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 176.77% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 22.02, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 228.97M shares, increasing 0.04% quarter-over-quarter.
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Ticker SymbolADMA
CompanyADMA Biologics Inc
CEOGrossman (Adam S)
Websitehttps://www.admabiologics.com/
FAQs
What is the current price of ADMA Biologics Inc (ADMA)?
The current price of ADMA Biologics Inc (ADMA) is 19.299.
What is the symbol of ADMA Biologics Inc?
The ticker symbol of ADMA Biologics Inc is ADMA.
What is the 52-week high of ADMA Biologics Inc?
The 52-week high of ADMA Biologics Inc is 25.670.
What is the 52-week low of ADMA Biologics Inc?
The 52-week low of ADMA Biologics Inc is 13.500.
What is the market capitalization of ADMA Biologics Inc?
The market capitalization of ADMA Biologics Inc is 4.60B.
What is the net income of ADMA Biologics Inc?
The net income of ADMA Biologics Inc is 197.67M.
Is ADMA Biologics Inc (ADMA) currently rated as Buy, Hold, or Sell?
According to analysts, ADMA Biologics Inc (ADMA) has an overall rating of Buy, with a price target of 27.250.
What is the Earnings Per Share (EPS TTM) of ADMA Biologics Inc (ADMA)?
The Earnings Per Share (EPS TTM) of ADMA Biologics Inc (ADMA) is 0.887.